|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
66,921,000 |
Market
Cap: |
2.83(B) |
Last
Volume: |
1,212,774 |
Avg
Vol: |
1,000,279 |
52
Week Range: |
$38.26 - $93.23 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue, Lyra®, FreshCells, D3®, FastPoint®, ReadyCells®, Super E-Mix, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hodges Michelle A. |
SVP, General Counsel |
|
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
473 |
628 |
|
- |
|
Steward Randall J |
Chief Financial Officer |
|
2022-02-01 |
4 |
D |
$102.32 |
$60,369 |
D/D |
(590) |
20,023 |
|
- |
|
Steward Randall J |
Chief Financial Officer |
|
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,706 |
20,613 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2022-02-01 |
4 |
D |
$102.32 |
$47,374 |
D/D |
(463) |
28,377 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
879 |
28,840 |
|
- |
|
Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
|
2022-02-01 |
4 |
D |
$102.32 |
$16,780 |
D/D |
(164) |
7,809 |
|
- |
|
Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
|
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
473 |
7,973 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2022-02-01 |
4 |
D |
$102.32 |
$66,610 |
D/D |
(651) |
13,595 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,312 |
14,246 |
|
- |
|
Slacik Charles P |
Director |
|
2022-01-25 |
4 |
OE |
$15.74 |
$236,123 |
D/D |
12,086 |
24,067 |
|
- |
|
Steward Randall J |
Chief Financial Officer |
|
2022-01-16 |
4 |
D |
$114.88 |
$198,398 |
D/D |
(1,727) |
18,907 |
|
- |
|
Steward Randall J |
Chief Financial Officer |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,798 |
20,634 |
|
- |
|
Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
|
2022-01-16 |
4 |
D |
$114.88 |
$54,913 |
D/D |
(478) |
14,681 |
|
- |
|
Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,727 |
15,159 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2022-01-16 |
4 |
D |
$114.88 |
$279,388 |
D/D |
(2,432) |
12,934 |
|
- |
|
Kroll Werner |
SVP, R&D |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,606 |
15,366 |
|
- |
|
Bryant Douglas C |
President & CEO |
|
2022-01-16 |
4 |
D |
$114.88 |
$793,936 |
D/D |
(6,911) |
503,451 |
|
- |
|
Bryant Douglas C |
President & CEO |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
13,819 |
510,362 |
|
- |
|
Russell Edward Keith |
SVP, Business Development |
|
2022-01-16 |
4 |
D |
$114.88 |
$190,931 |
D/D |
(1,662) |
29,070 |
|
- |
|
Russell Edward Keith |
SVP, Business Development |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,606 |
30,732 |
|
- |
|
Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
|
2022-01-16 |
4 |
D |
$114.88 |
$76,740 |
D/D |
(668) |
7,500 |
|
- |
|
Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,727 |
8,168 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2022-01-16 |
4 |
D |
$114.88 |
$285,936 |
D/D |
(2,489) |
27,961 |
|
- |
|
Bujarski Robert Joseph |
Chief Operating Officer |
|
2022-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,606 |
30,450 |
|
- |
|
Hodges Michelle A. |
SVP, General Counsel |
|
2021-12-01 |
4 |
D |
$144.69 |
$12,009 |
D/D |
(83) |
155 |
|
- |
|
799 Records found
|
|
Page 3 of 32 |
|
|